Wang Haotian, Wan Xin, Zhang Ying, Guo Jing, Bai Ou
Department of Hematology, The First Hospital of Jilin University, Changchun, Jilin, China.
Front Oncol. 2024 Jan 25;14:1327309. doi: 10.3389/fonc.2024.1327309. eCollection 2024.
Marginal zone lymphoma (MZL) is the second most common subtype of inert B-cell non-Hodgkin's lymphoma, accounting for 5-15% of non-Hodgkin's lymphoma cases. Patients with MZL have a long survival period, with a median survival of >10 years, and patients treated with a combination of anti-CD20 monoclonal antibody can achieve an overall effective rate of 81%. However, 20% of patients with MZL show relapse or experience disease progression within 2 years, with a median survival of only 3-5 years. Currently, the treatment options for patients with relapsed/refractory (R/R) MZL are limited, underscoring the pressing need for novel therapeutic drugs. The advent of novel anti-CD20 monoclonal antibodies, small molecule kinase inhibitors, immunomodulators, and other therapeutic strategies has ushered in a new era in the treatment of R/R MZL. Our objective is to summarize the existing treatment strategies, including immunotherapy and the emergent targeted therapies, and to evaluate their effectiveness and safety in the management of R/R MZL. By doing so, we aim to provide a clear understanding of the therapeutic landscape for R/R MZL, and to guide future research directions toward improving the prognosis and quality of life for patients afflicted with this challenging disease.
边缘区淋巴瘤（MZL）是惰性B细胞非霍奇金淋巴瘤的第二常见亚型，占非霍奇金淋巴瘤病例的5%-15%。MZL患者生存期较长，中位生存期>10年，接受抗CD20单克隆抗体联合治疗的患者总有效率可达81%。然而，20%的MZL患者在2年内出现复发或疾病进展，中位生存期仅为3-5年。目前，复发/难治性（R/R）MZL患者的治疗选择有限，这凸显了对新型治疗药物的迫切需求。新型抗CD20单克隆抗体、小分子激酶抑制剂、免疫调节剂及其他治疗策略的出现，为R/R MZL的治疗开启了新纪元。我们的目的是总结现有的治疗策略，包括免疫疗法和新兴的靶向疗法，并评估它们在R/R MZL治疗中的有效性和安全性。通过这样做，我们旨在清晰了解R/R MZL的治疗现状，并为改善这种具有挑战性疾病患者的预后和生活质量的未来研究方向提供指导。
